Growth Factors

Endocrine Pathology

Volumn 8, Issue 2, 1997, Pages 121-127

  Lloyd, Ricardo V ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cell cycle; Endocrine tissues; Growth factors; Pituitary; Receptor; Transforming growth factor

Indexed keywords

EID: 0001089192     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02739940     Document Type: Article

References (65)

1. Pusztai L, Lewis CE, Lorenzen J, McGhee JOD. Growth factors: regulation of normal and neoplastic growth. J Pathol 169:191-201, 1993.
2. Oberg K. Expression of growth factors and their receptors in neuroendocrine gut and pancreatic tumors and prognostic factors for survival. Ann NY Acad Sci 733:46-55, 1994.
3. Goustin AS, Leof EB, Shiples GD, Moses HL. Growth factors and cancer. Cancer Res 46:1015-1029, 1986.
4. Heldin CH, Westermark B. Growth factors-mechanisms of action and relation to oncogenes. Cell 37:9-20, 1984.
5. Mannes LM, Kastin AJ, Weber JT, Bank WA, Beckma BS, Zadina JE. The neurotrophins and their receptors: structure, function, and neuropathology. Neurosci Behav Rev 18:143-159, 1994.
6. Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 73:311-331, 1995.
7. Cullen KJ, Yee D, Rosen N. Insulin-like growth factors in human malignancy. Cancer Invest 9:443-454, 1991.
8. Ross R, Bowen-Pope DF, Raines EW. Platelet-derived growth factor and its role in health and disease. Phil Trans R Soc Lond Ser B 327:155-169, 1990.
9. Oka Y, Orth DN. Human plasma epidermal growth factor burogastron is associated with blood platelets. J Clin Invest 72:249-259, 1983.
10. Massague J. The transforming growth factor-β family. Annu Rev Cell Biol 6:597-641, 1990.
11. Brachmann R, Lindquist PB, Nagashima M, Kohr W, Lipari T, Napier M, Derynck R. Transmembrane TGFα precursors activate EGF/TGFα receptors. Cell 56:691-700, 1989.
12. Plowman GD, Green JM, McDonald VL, Neubauer MG, Disteche CM, Todaro GJ, Shoyab M. The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumour-inhibitory activity. Mol Cell Biol 10:1969-1981, 1990.
13. Burgess WH, Maciag T. The heparin-binding growth factor family of proteins. Annu Rev Biochem 58:575-606, 1989.
14. Heldin CH, Westermark B. Platelet-derived growth factor: three isoforms and two receptor types. Trans Genet 5:108-111, 1989.
15. Bernard JA, Lyons RM, Moses HL. The cell biology of transforming growth factor-β. Biochem Biophys Acta 1032:79-87, 1990.
16. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 342:440-443, 1989.
17. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hogiwara K, Usuki K, Takaku F, Risau W, Heldin CH. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338:557-561, 1989.
18. Shichiri M, Hirata Y, Nakajima T, Ando K, Imar T, Yanagisawa M, Masaki T, Marumo F. Endothelin-1 is an autocrine paracrine growth factor for human cancer cell lines. J Clin Invest 87:1867-1871, 1991.
19. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol 9:617-648, 1991.
20. O'Reilly MS, Holmgren L, Shiny Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994.
21. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996.
22. Robinson CJ. Multiple receptors found for the growing FGF family. TiPS 12:123,124, 1991.
23. Partanen J, Makela TP, Eerola E, et al. FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J 10:1347-1354, 1991.
24. Vaisman N, Gospodarowitz D, Neufeld G. Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 265:19,461-19,466, 1990.
25. Avivi A, Zimmer Y, Yayon A, Yarden Y, Givol D. Flg-2, a new member of fibroblast growth factor receptors. Oncogene 6:1089-1092, 1991.
26. Eismann A, Ahn JA, Graziani G, Tronick SR, Ron D. Alternative splicing generates at least five different isoforms of the human basic FGF receptor. Oncogene 6:1195-1202, 1991.
27. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841-848, 1991.
28. Bottario DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802-804, 1991.
29. Patterson JC, Childs GV. Nerve growth factor and its receptor in the anterior pituitary. Endocrinology 135:1689-1696, 1994.
30. Ezzat S, Walpola IA, Ramyor L, Smyth HS, Asa SL. Membrane-anchored expression of transforming growth factor-α in human pituitary adenoma cells. J Clin Endocrinol Metab 80:534-539, 1995.
31. Ezzat S, Melmed S. The role of growth factors in the pituitary. J Endocrinol Invest 13:691-698, 1990.
32. Silverlight JJ, Prysor-Jones RA, Jenkins JS. Basic fibroblast growth factor in human pituitary tumors. Clin Endocrinol 32:669-676, 1990.
33. Halper J, Parnell PG, Carter BJ, Reu P, Scheithauer BW. Presence of growth factors in human pituitary. Lab Invest 66:639-645, 1992.
34. Sporn MB, Roberts AB. Transforming growth factor-β: recent prognosis and new challenges. J Cell Biol 119:1017-1021, 1992.
35. Alexandrow MG, Moses HL. Transforming growth factor β and cell cycle regulation. Cancer Res 55:1452-1459, 1995.
36. Herman ME, Katzenllenbogen BS. Alterations in transforming growth factor-α and -β production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 54:5867-5874, 1994.
37. Wrana JL, Altisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGFβ receptor. Nature 370:341-347, 1994.
38. Segarini PR. TGFβ receptors: a complicated system of multiple binding proteins. Biochem Biophy Acta 1155:269-275, 1993.
39. Kingsley DM. The TGFβ superfamily. New members, new receptors, and new genetic tests of function in different organisms. Genes Dev 8:133-146, 1994.
40. Massague J, Polyak K. Mammalian antiproliferative signals and their targets. Curr Opinion Gen Dev 5:91-96, 1995.
41. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:693-699, 1992.
42. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90:770-774, 1993.
43. Sim L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang X-F, Brattain MG. Expression of transforming growth factor-β type II receptor leads to reduced malignancy in human breast cancer MCF 7 cells. J Biol Chem 269:26,449-26,455, 1994.
44. Park K, Kim SJ, Bany YJ, Park JG, Kim NK, Roberts AB, Sporn MB. Genetic changes in the transforming growth factor-β (TGFβ) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGFβ. Proc Natl Acad Sci USA 91:8772-8776, 1994.
45. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV. Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability. Science 268:1336-1338, 1996.
46. Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, Gesmander J, Vellucci VF, Reiss M. Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous cell carcinoma cells. Cancer Res 55:3982-3987, 1995.
47. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibor JA, Kim JH, Kato M, Lee C. Genetic changes in transforming growth factor β (TGFβ) receptor type gene correlates with insensitivity to TGFβ human prostate cancer cells. Cancer Res 56:44-48, 1996.
48. Garrigue Antar L, Souza RF, Vellucci VF, Meltzer SJ, Reiss M. Loss of transforming growth factor-β type II receptor expression in primary human esophageal cancer. Lab Invest 75:263-272, 1996.
49. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibur JA, Kim JH, Kato M, Lee C. Genetic changes in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β in human prostate cancer cells. Cancer Res 56:44-48, 1996.
50. Sorrentino V. Growth factors, growth inhibitors, and cell cycle control. Anticancer Res 9:1925-1936, 1989.
51. Schneider C, King RM, Philipson L. Genes specifically expressed at growth arrest of mammalian cells. Cell 54:787-793, 1988.
52. Pepperkok R, Zanetti M, King R, Delia D, Ansorse W, Philipson L, Schneider C. Automatic microinjection system facilitates detection of growth inhibitory mRNA. Proc Natl Acad Sci USA 85:6748-6752, 1988.
53. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massague J. Growth inhibition linked to suppression of retinoblastoma protein phosphorylation. Cell 62:175-185, 1990.
54. Sherr CJ. G1 phase progression: cycling on cue. Cell 79:551-555, 1994.
55. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573-582, 1994.
56. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995.
57. Kamb A. Cell- cycle regulators and cancer. Trends Genet 11.136-140, 1995.
58. INK4B is a potential effector of TGFβ- induced cell cycle arrest. Nature 371:257-261, 1994.
59. kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720, 1996.
60. kip1. Cell 85:721-732, 1996.
61. kip1-deficient mice. Cell 85:733-744, 1996.
62. kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994.
63. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to P21. Cell 78:67-74, 1994.
64. kip1. J Clin Invest 97:1983-1988, 1996.
65. kip1 expression in endocrine and other tumors. Am J Pathol 150:401-407, 1997.